Company registration number 13886983 (England and Wales)
OXFORD TARGET THERAPEUTICS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2025
PAGES FOR FILING WITH REGISTRAR
OXFORD TARGET THERAPEUTICS LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 6
OXFORD TARGET THERAPEUTICS LIMITED
BALANCE SHEET
AS AT
31 JULY 2025
31 July 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
212,202
212,202
Tangible assets
5
555
-
0
212,757
212,202
Current assets
Debtors
6
-
0
12,535
Cash at bank and in hand
62,399
56,279
62,399
68,814
Creditors: amounts falling due within one year
7
(79,062)
(78,225)
Net current liabilities
(16,663)
(9,411)
Net assets
196,094
202,791
Capital and reserves
Called up share capital
8
4
4
Profit and loss reserves
196,090
202,787
Total equity
196,094
202,791

For the financial year ended 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 18 November 2025 and are signed on its behalf by:
Dr V M Bolanos-Garcia
Director
Company registration number 13886983 (England and Wales)
OXFORD TARGET THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2025
- 2 -
1
Accounting policies
Company information

Oxford Target Therapeutics Limited is a private company limited by shares incorporated in England and Wales. The registered office is Bioinnovation Hub, Tonge Building Oxford Brookes University, Gipsy Lane, Headington Campus, Oxford, Oxfordshire, United Kingdom, OX3 0BP.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Development costs
7 years straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

OXFORD TARGET THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
1
Accounting policies
(Continued)
- 3 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
3 years straight line
1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in bank only.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include other debtors, corporation tax recoverable, and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including taxation and social security, and other creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

1.9
Compound instruments

The component parts of compound instruments issued by the company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortised cost basis using the effective interest method until extinguished upon conversion or at the instrument's maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognised and included in equity net of income tax effects and is not subsequently remeasured.

OXFORD TARGET THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
1
Accounting policies
(Continued)
- 4 -
1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the fixed assets.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.15
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

OXFORD TARGET THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
- 5 -
3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
2
4
Intangible fixed assets
Development costs
£
Cost
At 1 August 2024 and 31 July 2025
212,202
Amortisation and impairment
At 1 August 2024 and 31 July 2025
-
0
Carrying amount
At 31 July 2025
212,202
At 31 July 2024
212,202
5
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 August 2024
-
0
Additions
666
At 31 July 2025
666
Depreciation and impairment
At 1 August 2024
-
0
Depreciation charged in the year
111
At 31 July 2025
111
Carrying amount
At 31 July 2025
555
At 31 July 2024
-
0
OXFORD TARGET THERAPEUTICS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2025
- 6 -
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Corporation tax recoverable
-
0
11,406
Other debtors
-
0
1,129
-
0
12,535
7
Creditors: amounts falling due within one year
2025
2024
£
£
Convertible loans
58,975
55,975
Taxation and social security
487
-
0
Other creditors
19,600
22,250
79,062
78,225
8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £0.00001 each
400,000
400,000
4
4
2025-07-312024-08-01falsefalsefalse18 November 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityDr V M Bolanos-GarciaMiss N L CurtisDr L A King2025-11-18138869832024-08-012025-07-31138869832025-07-31138869832024-07-3113886983core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-07-3113886983core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-07-3113886983core:OtherPropertyPlantEquipment2025-07-3113886983core:OtherPropertyPlantEquipment2024-07-3113886983core:CurrentFinancialInstrumentscore:WithinOneYear2025-07-3113886983core:CurrentFinancialInstrumentscore:WithinOneYear2024-07-3113886983core:CurrentFinancialInstruments2025-07-3113886983core:CurrentFinancialInstruments2024-07-3113886983core:ShareCapital2025-07-3113886983core:ShareCapital2024-07-3113886983core:RetainedEarningsAccumulatedLosses2025-07-3113886983core:RetainedEarningsAccumulatedLosses2024-07-3113886983core:ShareCapitalOrdinaryShareClass22025-07-3113886983core:ShareCapitalOrdinaryShareClass22024-07-3113886983bus:Director12024-08-012025-07-3113886983core:IntangibleAssetsOtherThanGoodwill2024-08-012025-07-3113886983core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-08-012025-07-3113886983core:ComputerEquipment2024-08-012025-07-31138869832023-08-012024-07-3113886983core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-07-3113886983core:OtherPropertyPlantEquipment2024-07-3113886983core:OtherPropertyPlantEquipment2024-08-012025-07-3113886983bus:PrivateLimitedCompanyLtd2024-08-012025-07-3113886983bus:SmallCompaniesRegimeForAccounts2024-08-012025-07-3113886983bus:FRS1022024-08-012025-07-3113886983bus:AuditExemptWithAccountantsReport2024-08-012025-07-3113886983bus:Director22024-08-012025-07-3113886983bus:Director32024-08-012025-07-3113886983bus:FullAccounts2024-08-012025-07-31xbrli:purexbrli:sharesiso4217:GBP